|
FOR: ALTAIR NANOTECHNOLOGIES, INC. 
Altair Nanotechnologies Reports Third Quarter 2009 Financial Results NOV 5, 2009 - 06:00 ET RENO, NV--(Marketwire - November 5, 2009) - Altair Nanotechnologies, Inc. (Altairnano)
( For the quarter ended September 30, 2009, the Company reported revenues of $1.7 million, down from $1.8 million for the same period in 2008. The net loss was $3.3 million, or three cents per share, compared to a net loss of $9.1 million, or 11 cents per share, for the third quarter of 2008. The basic and diluted weighted average shares outstanding for the quarter were 105.1 million, compared to 84.6 million reported in the third quarter of 2008. Operating expenses of $5.9 million for the third quarter of 2009 were $5.2 million less than the operating expenses of $11.1 million for the third quarter of 2008. The third quarter of 2008 contained the one-time settlement expense of $3.6 million with Al Yousuf LLC. and higher research and development costs associated with the number of grants being worked on in 2008 compared to 2009. Additionally, we had reduced spending associated with the former Life Sciences and Performance Materials groups in 2009 than we did in 2008. The Company's cash and cash equivalents decreased by $4.1 million, from $28.1 million at December 31, 2008 to $23.9 million at September 30, 2009. This is due primarily to net cash used in operations of approximately $18.1 million, $4.8 million of which was for increased product inventories; investing activities primarily consisting of purchases of fixed assets of approximately $0.6 million offset by $2.0 million received from the sale of our Spectrum common stock; and financing activities that include payment of notes payable of $0.6 million offset by $12.8 million of proceeds relating to the issuance of common shares in May 2009. The Company's cash burn rate has been higher throughout the first three quarters of 2009 than it was in the second half of 2008 as the Company has been building up inventory of component parts with three to six month lead times in anticipation of sales later this year and in early 2010. We expect our cash burn rate to slow in the fourth quarter of 2009 as the Company believes it now has adequate levels of components in inventory. Product inventories are higher by $3.6 million and prepaid expenses by $1.2 million from their respective December 31, 2008 balances. The increase in prepaid expenses results almost entirely from a partial payment on the purchase of battery cells from the Company's Korean cell manufacturer. "We have experienced an increased level of customer requests for quotes in the past couple of months," said Dr. Terry Copeland, Altairnano's president and CEO. "In addition, we anticipate that potential order activity will begin to gain traction as we enter into 2010. Given the importance of establishing this revenue stream and having referenceable customers for other prospects to speak with, we need to be able to move expeditiously once we have these initial firm orders." During the third quarter Altairnano received the final signed contracts for both the $3.8 million Office of Naval Research phase 2 development program, and the Department of Defense supported $1.8 million nanosensor project. The Company will perform work on both of these contracts during the fourth quarter and into the first half of 2010. As payment for Spectrum Pharmaceuticals achieving certain past milestones as specified in its contract with the Company, Altairnano was carrying shares of Spectrum stock with a cost basis of $1.1 million on its balance sheet. As a result of the increasing share price for this stock during the third quarter of 2009, the Company sold these shares for $2.0 million realizing a gain of $900,000. Altairnano also reached agreement with Spectrum to modify its existing contract to assign ownership of all patent rights associated with Renazorb™ and Renalan™ compounds to Spectrum. Under the terms of the agreement, the Company received $750,000 in Spectrum restricted common stock and a right to future royalties and milestone payments upon completion of certain specified events. Third Quarter 2009 Conference Call Altairnano will hold a conference call to discuss its third quarter 2009 results on Thursday, November 5, 2009 at 11:00 a.m. Eastern Standard Time (EST). Shareholders and members of the investment community are invited to participate in the conference call. The dial-in number for both U.S. and international callers is +1 719-325-2117. Please dial in to the conference five minutes before the call is scheduled to begin. Ask the operator for the Altair Nanotechnologies call. An audio replay of the conference call will be available from 12:00 p.m. EST, Thursday, November 5, until Midnight EST, November 12, 2009. It can be accessed by dialing +1 719-457-0820 and entering conference number 1046971. Additionally, the conference call and replay will be available online, and can be accessed by visiting Altairnano's web site, www.altairnano.com. About Altair Nanotechnologies, Inc. Headquartered in Reno, Nevada with manufacturing in Anderson, Indiana, Altairnano is a leading provider of energy storage systems for clean, efficient power and energy management. Going beyond lithium ion, Altairnano's Lithium-Titanate based battery systems are among the highest performing and most scalable, with applications that include battery cells for military artillery, battery packs for hybrid vehicles and energy storage systems for large-scale stationary power services. For more information please visit Altairnano at www.altairnano.com. Forward-Looking Statements This release may contain forward-looking statements as well as historical information. Forward-looking statements, which are included in accordance with the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, may involve risks, uncertainties and other factors that may cause Altairnano's actual results and performance in future periods to be materially different from any future results or performance suggested by the forward-looking statements in this release. These risks and uncertainties include, without limitation, the risks that development of any the early-stage products of the Company will not be completed for technical, business or other reasons; that any products under development or in the early commercial stages will not perform as expected in future testing or commercial applications; that customers or prospective customers will not use or purchase products as represented to us or otherwise expected for various reasons, including a buyer's purchasing of a competing product, absence of agreement over pricing or a buyer's absence of capital to purchase products; that one or more of the joint development partners or customers may proceed slowly with, or abandon, development or commercialization efforts for any of various reasons, including concerns with the feasibility of the product or the financial viability of continuing with our products or their product; that sales of commercialized Altairnano products may not reach expected levels for one or more reasons, including the failure of end products to perform as expected or the introduction of a superior product; that costs associated with the proposed products may exceed revenues; and that, due to unexpected expenses not accompanied by offsetting revenue, the Company's use of cash in its operations may exceed budgeted levels. In general, Altairnano is, and expects to be in the immediate future, dependent upon funds generated from sales of securities, grants, testing agreements, and licensing agreements to fund its testing, development and ongoing operations. In addition, other risks are identified in the Company's most recent Annual Report on Form 10-K filed with the SEC. Such forward-looking statements speak only as of the date of this release. The Company expressly disclaims any obligation to update or revise any forward-looking statements found herein to reflect any changes in Company expectations or results or any change in events.
Tables Follow
ALTAIR NANOTECHNOLOGIES INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Expressed in thousands of United States Dollars, except shares and per
share amounts)
(Unaudited)
September 30, December 31,
2009 2008
------------- -------------
ASSETS
Current assets
Cash and cash equivalents $ 23,939 $ 28,088
Restricted cash 1 -
Investment in available for sale securities 766 -
Accounts receivable, net 620 955
Product inventories 3,715 98
Prepaid expenses and other current assets 1,838 572
------------- -------------
Total current assets 30,879 29,713
Investment in available for sale securities 3,277 3,174
Property, plant and equipment, net held and
used 10,729 11,637
Property, plant and equipment, net held and
not used 1,823 2,377
Patents, net 572 636
Other assets 500 534
------------- -------------
Total Assets $ 47,780 $ 48,071
============= =============
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities
Trade accounts payable $ 1,625 $ 749
Accrued salaries and benefits 1,789 1,361
Accrued warranty 33 36
Accrued liabilities 763 765
Current portion of long-term debt 925 736
------------- -------------
Total current liabilities 5,135 3,647
------------- -------------
Long-term debt, less current portion 41 608
Stockholders' equity
Common stock, no par value, unlimited shares
authorized; 105,519,855 and 93,143,271 shares
issued and outstanding at September 30, 2009
and December 31, 2008 188,525 180,105
Additional paid in capital 10,735 5,378
Accumulated deficit (156,987) (140,892)
Accumulated other comprehensive loss (611) (1,873)
------------- -------------
Total Altair Nanotechnologies, Inc's
stockholders' equity 41,662 42,718
Noncontrolling interest in subsidiary 942 1,098
------------- -------------
Total stockholders' equity 42,604 43,816
------------- -------------
Total liabilities and stockholders' equity $ 47,780 $ 48,071
============= =============
ALTAIR NANOTECHNOLOGIES INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Expressed in thousands of United States Dollars, except share and per
share amounts)
(Unaudited)
Three Months Ended Nine Months Ended
September 30, September 30,
------------------------ ------------------------
2009 2008 2009 2008
----------- ----------- ----------- -----------
Revenues
License fees $ 750 $ - $ 750 $ -
Product sales 409 166 662 555
Less sales returns - - (183) -
Commercial
collaborations 122 129 888 1,642
Contracts and grants 386 1,507 449 2,577
----------- ----------- ----------- -----------
Total net revenues 1,667 1,802 2,566 4,774
----------- ----------- ----------- -----------
Operating expenses
Cost of sales - product 171 59 519 138
Cost of sales - warranty
and inventory reserves 68 - 68 (2,865)
Research and development 2,219 3,320 7,516 13,690
Sales and marketing 761 661 1,969 2,096
Notes receivable
extinguishment - - - 1,722
Settlement and release - 3,605 - 3,605
General and
administrative 2,001 2,756 7,598 8,459
Depreciation and
amortization 686 724 2,093 1,937
----------- ----------- ----------- -----------
Total operating
expenses 5,906 11,125 19,763 28,782
----------- ----------- ----------- -----------
Loss from operations (4,239) (9,323) (17,197) (24,008)
----------- ----------- ----------- -----------
Other income (expense)
Interest expense (61) (23) (92) (73)
Interest income 38 180 157 810
Realized gain on
investment 868 - 850 -
Gain/(Loss) on
foreign exchange - (1) (2) (5)
----------- ----------- ----------- -----------
Total other
income, net 845 156 913 732
----------- ----------- ----------- -----------
Net loss (3,394) (9,167) (16,284) (23,276)
Less: Noncontrolling
interests' share 78 56 189 216
----------- ----------- ----------- -----------
Net loss attributable
to Altair
Nanotechnologies, Inc. $ (3,316) $ (9,111) $ (16,095) $ (23,060)
=========== =========== =========== ===========
Loss per common share -
basic and diluted $ (0.03) $ (0.11) $ (0.16) $ (0.27)
=========== =========== =========== ===========
Weighted average shares
- basic and diluted 105,089,234 84,635,878 98,521,157 84,448,743
=========== =========== =========== ===========
FOR FURTHER INFORMATION PLEASE CONTACT:
For Additional Information:
Institutional Investors:
Brion D. Tanous
Principal
CleanTech IR, Inc.
310-541-6824
Email Contact
Individual Investors:
Tom Herbert
Principal
CleanTech IR, Inc.
310-541-6824
Email Contact
Media Relations:
Jeff Brunings
Director, Strategic Marketing
Altair Nanotechnologies, Inc.
775-856-2500
Email Contact
|
